ResearcherUniversity of MinnesotaNo recent work listed
Zhiyu Chen
Matched on ORCID iD 0000-0002-9707-3390; OpenAlex author ID A5100626002. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper
Papers 6
- Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Last author DOI 10.1097/as9.0000000000000273↗
- Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. Last author DOI 10.1155/2022/9202531↗
- Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1. Last author DOI 10.1016/j.phymed.2019.152953↗
- PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s41419-019-1839-z↗
- Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Co-author DOI 10.1016/j.canlet.2014.03.016↗
- miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Co-author DOI 10.1186/1476-4598-12-105↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xingxing Su · 3 shared papers, 2019–2023 · strength 0.50
- Paper Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pan… DOI 10.1097/as9.0000000000000273↗
- Paper Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. DOI 10.1155/2022/9202531↗
- Paper PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcino… DOI 10.1038/s41419-019-1839-z↗
- Yishi Yang · 3 shared papers, 2019–2023 · strength 0.50
- Paper Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pan… DOI 10.1097/as9.0000000000000273↗
- Paper Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. DOI 10.1155/2022/9202531↗
- Paper PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcino… DOI 10.1038/s41419-019-1839-z↗
- Zhi-Peng Liu · 2 shared papers, 2022–2023 · strength 0.40
- Haisu Dai · 3 shared papers, 2019–2022 · strength 0.40
- Paper Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. DOI 10.1155/2022/9202531↗
- Paper Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1. DOI 10.1016/j.phymed.2019.152953↗
- Paper PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcino… DOI 10.1038/s41419-019-1839-z↗
- Ping Bie · 2 shared papers, 2019 · strength 0.22
- Paper Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1. DOI 10.1016/j.phymed.2019.152953↗
- Paper PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcino… DOI 10.1038/s41419-019-1839-z↗
- Sulagna Banerjee · 2 shared papers, 2013–2014 · strength 0.08
- Selwyn Maurice Vickers · 2 shared papers, 2013–2014 · strength 0.08
- Ashok Kumar Saluja · 2 shared papers, 2013–2014 · strength 0.08
- Vikas Dudeja · 2 shared papers, 2013–2014 · strength 0.08
- Rohit Chugh · 1 shared paper, 2014 · strength 0.05
- Tiffany N. MacKenzie · 1 shared paper, 2013 · strength 0.04
- Huaizhi Wang · 1 shared paper, 2013 · strength 0.04
- Xiaowu Li · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.